https://retacompare.com/news/survey-reveals-key-factors-influencing-glp-1-drug-satisfaction 2026-10-27T17:45:15.000Z RetatrutideCompare en 2026-10-27T17:45:15.000Z Survey Reveals Key Factors Influencing GLP-1 Drug Satisfaction Patient Experiences, Retatrutide https://retacompare.com/news/court-denies-novo-s-attempt-to-halt-lilly-s-obesity-drug-advertisements 2026-10-27T16:08:55.000Z RetatrutideCompare en 2026-10-27T16:08:55.000Z Court Denies Novo's Attempt to Halt Lilly's Obesity Drug Advertisements Market News, Retatrutide https://retacompare.com/news/glp-1-agonists-linked-to-reduced-kidney-failure-risk-in-obesity-ckd 2026-10-27T16:08:32.000Z RetatrutideCompare en 2026-10-27T16:08:32.000Z GLP-1 Agonists Linked to Reduced Kidney Failure Risk in Obesity, CKD Clinical Trials, Retatrutide https://retacompare.com/news/court-denies-novo-s-attempt-to-halt-lilly-s-obesity-drug-advertising 2026-10-27T16:03:00.000Z RetatrutideCompare en 2026-10-27T16:03:00.000Z Court Denies Novo's Attempt to Halt Lilly's Obesity Drug Advertising Market News, Retatrutide https://retacompare.com/news/concerns-about-glp-1s-for-weight-loss-highlighted-in-recent-report 2026-10-27T13:00:14.000Z RetatrutideCompare en 2026-10-27T13:00:14.000Z Concerns About GLP-1s for Weight Loss Highlighted in Recent Report Weight Loss, Retatrutide https://retacompare.com/news/patient-satisfaction-with-glp-1-weight-loss-drugs-explored 2026-10-27T08:50:32.000Z RetatrutideCompare en 2026-10-27T08:50:32.000Z Patient Satisfaction with GLP-1 Weight Loss Drugs Explored Patient Experiences, Retatrutide https://retacompare.com/news/glp-1-agonist-misinformation-challenges-primary-care-providers 2026-10-27T08:34:49.000Z RetatrutideCompare en 2026-10-27T08:34:49.000Z GLP-1 Agonist Misinformation Challenges Primary Care Providers Patient Experiences, Retatrutide https://retacompare.com/news/glp-1-drugs-examining-benefits-and-risks-in-eating-disorders 2026-10-27T03:28:25.000Z RetatrutideCompare en 2026-10-27T03:28:25.000Z GLP-1 Drugs: Examining Benefits and Risks in Eating Disorders Weight Loss, Retatrutide https://retacompare.com/news/obesity-scheme-leader-received-payments-from-glp-1-drug-companies 2026-10-27T00:00:00.000Z RetatrutideCompare en 2026-10-27T00:00:00.000Z Obesity Scheme Leader Received Payments from GLP-1 Drug Companies Market News, Retatrutide